Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Feb 28 04:00PM ET
Dollar change
Percentage change
IndexRUT P/E- EPS (ttm)-3.91 Insider Own6.81% Shs Outstand50.62M Perf Week-2.51%
Market Cap275.37M Forward P/E- EPS next Y-1.62 Insider Trans-3.78% Shs Float47.17M Perf Month55.87%
Income-183.89M PEG- EPS next Q-1.04 Inst Own96.10% Short Float12.31% Perf Quarter198.90%
Sales145.88M P/S1.89 EPS this Y38.78% Inst Trans-1.54% Short Ratio3.52 Perf Half Y0.37%
Book/sh6.05 P/B0.90 EPS next Y62.92% ROA-27.25% Short Interest5.81M Perf Year-60.41%
Cash/sh4.95 P/C1.10 EPS next 5Y- ROE-58.41% 52W Range1.53 - 12.69 Perf YTD27.40%
Dividend Est.- P/FCF- EPS past 5Y- ROI-33.17% 52W High-57.13% Beta1.88
Dividend TTM- Quick Ratio4.08 Sales past 5Y86.20% Gross Margin73.49% 52W Low254.40% ATR (14)0.48
Dividend Ex-Date- Current Ratio4.08 EPS Y/Y TTM59.17% Oper. Margin-126.12% RSI (14)54.89 Volatility8.80% 11.99%
Employees425 Debt/Eq0.85 Sales Y/Y TTM184.07% Profit Margin-126.06% Recom2.25 Target Price10.67
Option/ShortYes / Yes LT Debt/Eq0.81 EPS Q/Q20.46% Payout- Rel Volume0.00 Prev Close5.44
Sales Surprise-61.51% EPS Surprise-21.85% Sales Q/Q-10.25% EarningsNov 14 BMO Avg Volume1.65M Price5.44
SMA20-3.01% SMA5021.93% SMA200-7.21% Trades Volume0 Change0.00%
Date Action Analyst Rating Change Price Target Change
Jan-31-24Upgrade Leerink Partners Market Perform → Outperform $5 → $18
Jan-31-24Downgrade TD Cowen Outperform → Market Perform
Oct-30-23Downgrade Leerink Partners Outperform → Market Perform $6
Oct-12-23Initiated Citigroup Buy $13
Sep-13-23Downgrade Goldman Buy → Neutral $5
Sep-12-23Downgrade Guggenheim Buy → Neutral
Jul-28-23Downgrade Morgan Stanley Overweight → Equal-Weight $25 → $13
Oct-31-22Initiated Guggenheim Buy $30
May-02-22Initiated Goldman Buy $26
Feb-10-22Initiated SVB Leerink Outperform $38
Feb-27-24 08:00AM
Feb-05-24 04:05PM
Feb-01-24 08:27AM
Jan-31-24 11:11AM
07:01AM Loading…
Jan-30-24 07:01AM
Jan-12-24 12:00PM
Dec-11-23 07:30PM
Dec-06-23 02:00PM
Nov-20-23 12:02PM
Nov-14-23 07:00AM
Nov-10-23 07:00AM
Sep-12-23 07:00AM
06:55AM Loading…
Sep-06-23 07:00AM
Aug-24-23 09:00PM
Aug-14-23 07:00AM
Aug-08-23 07:00AM
Aug-01-23 04:15PM
Jun-14-23 07:00AM
Jun-07-23 07:00AM
May-19-23 06:00AM
May-17-23 07:17AM
May-11-23 12:37PM
May-03-23 04:05PM
May-02-23 04:37PM
May-01-23 07:00AM
08:30AM Loading…
Apr-28-23 08:30AM
Apr-17-23 06:59AM
Mar-16-23 04:05PM
Mar-08-23 08:30AM
Mar-03-23 07:00AM
Mar-01-23 09:00AM
Feb-28-23 09:00PM
Feb-10-23 11:13AM
Feb-01-23 07:30AM
Jan-18-23 11:35AM
Jan-09-23 08:00AM
Jan-06-23 09:11AM
Nov-07-22 04:05PM
Nov-03-22 09:06AM
Oct-27-22 07:00AM
Sep-07-22 07:00AM
Aug-31-22 07:30AM
Aug-12-22 06:23AM
Aug-10-22 06:50AM
Aug-04-22 07:02AM
Aug-03-22 07:30AM
Jul-04-22 03:30PM
Jun-06-22 07:30AM
May-12-22 04:05PM
May-04-22 09:10PM
Apr-08-22 04:15PM
Apr-07-22 07:30AM
Mar-22-22 07:00AM
Mar-16-22 08:41AM
Feb-14-22 07:30AM
Feb-11-22 09:58AM
Feb-03-22 01:38PM
Jan-26-22 08:00AM
Jan-11-22 07:00AM
Jan-06-22 07:00AM
Dec-13-21 06:15PM
Dec-01-21 07:00AM
Nov-15-21 10:43AM
Nov-10-21 04:30PM
2seventy Bio, Inc. operates as cell and gene therapy company. It is focused on the research, development, and commercialization of transformative treatments for cancer. The company was founded on April 26, 2021 and is headquartered in Cambridge, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Leschly NickPresident and CEOJan 05Sale3.751,5545,8331,085,476Jan 09 04:08 PM
Baird William D IIIChief Operating OfficerJan 05Sale3.751,3805,180161,335Jan 09 04:09 PM
Gregory Philip DChief Scientific OfficerJan 05Sale3.757952,984230,842Jan 09 04:09 PM
Leschly NickPresident and CEOJan 03Sale3.8772,312279,7391,087,030Jan 05 04:30 PM
Baird William D IIIChief Operating OfficerJan 03Sale3.8733,651130,179162,715Jan 05 04:29 PM
Gregory Philip DChief Scientific OfficerJan 03Sale3.8725,61399,084231,637Jan 05 04:30 PM
Leschly NickPresident and CEOAug 22Sale5.499,31251,0901,159,342Aug 24 05:04 PM
Baird William D IIIChief Financial OfficerAug 22Sale5.497,03138,576196,366Aug 24 05:04 PM
Gregory Philip DChief Scientific OfficerAug 22Sale5.496,15933,791257,250Aug 24 05:04 PM
Kynam Capital Management, LP10% OwnerAug 10Buy5.92515,4143,049,2875,953,825Aug 14 08:51 PM
Kynam Global Healthcare Master10% OwnerAug 10Buy5.92515,4143,049,2875,953,825Aug 16 07:11 PM
Kynam Global Healthcare Master10% OwnerAug 10Buy5.9686,414515,0275,142,111Aug 16 07:11 PM
Kynam Capital Management, LP10% OwnerAug 10Buy5.9686,414515,0275,142,111Aug 14 08:51 PM
Leschly NickPresident and CEOAug 03Sale6.139,06055,4991,168,654Aug 07 04:07 PM
Baird William D IIIChief Financial OfficerAug 03Sale6.136,90642,304203,397Aug 07 04:06 PM
Gregory Philip DChief Scientific OfficerAug 03Sale6.133,96624,295263,409Aug 07 04:06 PM